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Abstract: In-silico virtual trials offer significant advantages in cost, time and safety. However, no such 
method has been truly validated with clinical data. This study tests 2 matched cohorts from an 
independent ICU treated with 2 different glycaemic control protocols. The goal is to validate the in-silico 
virtual trials model and methods, including the underlying assumptions. A retrospective analysis used 
records from a 211 patient subset of the Glucontrol trial in Liege, Belgium. Glucontrol-A (N = 142) 
targeted a BG range of 4.4-6.1 mmol/L and Glucontrol-B (N = 69) targeted 7.8-10.0 mmol/L. Cohorts 
were matched by APACHE II score, but the Glucontrol A cohort was slightly older (p = 0.0352). Results 
showed high correlation between self- and cross-validation virtual trials and clinical results. The virtual 
trials models and methods are thus validated on independent data. 
Keywords: Intensive Care, in-silico trials, virtual trials, hyperglycaemia, model, validation. 
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1. INTRODUCTION 
Stress-induced hyperglycaemia and high insulin resistance 
are prevalent in critical care. Hyperglycaemia worsens 
outcomes, increasing the risk of severe infection, 
myocardial infarction (Capes et al. 2000), and critical 
illness polyneuropathy and multiple organ failure (Van den 
Berghe et al. 2001). Hence, hyperglycaemia is strongly 
associated with increased mortality. 
Van den Berghe et al (2001) showed that tight glucose 
control (TGC) reduced intensive care unit (ICU) patient 
mortality up to 45% using a target of 6.1mmol/L. Other 
studies with similar or higher targets have successfully 
reduced mortality (Krinsley 2004; Chase et al. 2008). 
Hence, the data indicate that a control algorithm that safely 
provides TGC to reduce hyperglycaemia and glycaemic 
variability has the potential to reduce mortality and cost 
(Krinsley and Jones 2006). 
In this study, “virtual trials” are performed using a 
clinically validated model (Chase et al. 2007) of the 
glucose-insulin system. Insulin sensitivity, SI, is used as 
the critical marker of a patient‟s metabolic state and is 
assumed independent of the model inputs. Virtual trials 
can be used to simulate a TGC protocol using a SI profile 
identified from clinical data and different insulin and 
nutrition inputs. Virtual trials enable the rapid testing of 
new TGC intervention protocols and analysing control 
protocol performance. They are thus a means of safely 
optimising protocols prior to implementation. 
Virtual patient trials have been used in design of TGC 
protocols (Chase et al. 2007). The clinical results of 
SPRINT (Chase et al. 2008) showed very close agreement 
to expected results from simulation (Chase et al. 2007). 
However, SPRINT was implemented in Christchurch 
Hospital ICU and was designed using clinical data and 
virtual patients from the same unit.  
Thus, the performance of virtual trials on separate cohorts, 
independent of the ICU used to generate the virtual 
patients, has not yet been evaluated. In addition, the virtual 
trials assumption of the model independence of a virtual 
patient‟s insulin sensitivity profile from intervention 
inputs, identified from patient data and the system model, 
has never been validated.  
In this study, the Glucontrol study (Preiser et al. 2009) 
provides a source of patient data independent of the 
Christchurch ICU. Only data from one Glucontrol centre 
(University Hospital of Liege, Belgium) were used. Self-
validation and cross-validation virtual trial simulations are 
used to assess model error and validate the overall virtual 
trials approach. 
2. METHODS 
2.1  Glucontrol Protocol and Patient Cohorts 
The Glucontrol trial (Preiser et al. 2009) randomised 
patients into two groups: A and B. Group A received 
intensive insulin therapy and Group B received 
  
     
 
conventional insulin therapy, with target BG ranges of 4.4-
6.1 mmol/L and 7.8-10.0 mmol/L respectively. The 
protocols are defined in (Preiser et al. 2009). Insulin was 
administered as a continuous IV infusion. Hourly BG 
measurements were taken when the glycaemic level was 
not within the target range. Otherwise, 2-hour 
measurements were taken in the case of limited variation 
of glycaemia, defined as less than a 50% change from the 
previous glycaemia in 2-hour range. Finally, 4-hour 
measurements were taken when the glycaemic level was 
less than 50% of the highest glycaemia of the four last 
hours. The protocol specified insulin infusion rates 
whereas nutritional input was left to local and/or clinician 
standards, and was not explicitly considered in the 
Glucontrol study. 
In this study, data was used from 350 patients treated using 
the Glucontrol protocol at CHU de Liege, Belgium, 
between March 2004 and April 2005. Patients were 
eliminated from the analysis if they received no insulin for 
their entire stay (per protocol), had less than 5 BG 
measurements or received little or no (recorded) 
carbohydrate administration (in any form) for more than 
48 hours of their stay. Clinical details of the resulting 
Glucontrol cohorts are in Table 1. Patients in Group A 
were slightly older than Group B. However, there were no 
significant differences in weight, BMI or severity of illness 
as measured by APACHE II score. 
2.2  Glucose-Insulin System Model 
The analysis of patient-specific insulin sensitivity uses a 
glucose insulin system model that has been clinically 
validated in several studies (Wong et al. 2006; Chase et al. 
2007): 
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Where: G(t) is the total plasma glucose, I(t) is the plasma 
insulin, and Q(t) is the effect of previously infused insulin 
being utilized over time. EGPmax is the theoretical 
maximum endogenous glucose production (EGP) for a 
patient, which is suppressed with increasing glucose 
concentrations. This suppression, independent of non-
insulin mediated glucose uptake by the central nervous 
system (CNS) is captured by the term pG. In contrast, 
patient-specific insulin mediated glucose removal is 
captured with insulin sensitivity, SI, which is identified 
from clinical data as a time-dependent variable that reflects 
evolving patient condition. Exogenous inputs are glucose 
appearance P(t) from the carbohydrate content of nutrition 
infusions via a two compartment model (Wong et al. 2006) 
and intravenous insulin administration uex(t). The 
remaining parameters are physiologically defined 
population constants for transport rates (n, k), saturation 
Table 1. Glucontrol A and B comparison (Median 
[IQR]). P-values computed using chi-squared and 
Mann-Whitney tests. 
Cohort A B P value 
Baseline Variables 
Number 142 69   
Percent male (%) 64.8 56.5 0.25 
Age 71 [61-80] 69 [53-77] 0.035 
Weight (kg) 72 [62-85] 75 [68-81] 0.38 
BMI 
25.4  
[22.6-29.3] 
26.0  
[23.2-29.3] 0.46 
APACHE II 17 [14-22] 17 [14-21] 0.76 
Initial BG 
6.6  
[5.56-8.56] 
6.6  
[5.65-9.36] 0.58 
Glucose Control 
Total hours 16, 831 12, 946   
BG measures 4, 571 2, 820   
BG (mmol/L) 
6.3  
[5.3-7.6] 
8.2  
[6.9-9.4]   
Insulin (U/hr) 
1.5  
[0.5-3.0] 
0.7  
[0.0-1.7]   
All glucose admin 
(mmol/min) 
0.30  
[0.00-0.90] 
0.60  
[0.10-1.00]   
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Collection of  
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II. In Silico Virtual Patient Simulation 
 Fig. 1. Virtual patient development and in-silico simulation 
method. (I) Clinical data is used for fitting insulin sensitivity 
profiles to create „virtual patients‟.  (II) These virtual patients 
can be used for simulating different protocols. 
 
  
     
 
parameters αG, αI), endogenous insulin secretion (IB, kI) or 
volumes (VG, VI). 
The essential parameter that drives the observed patient-
specific glycaemic response to insulin and nutrition inputs 
is insulin sensitivity, SI. The SI parameter is identified by 
fitting the model to retrospective blood glucose 
measurements, and insulin and carbohydrate 
administration inputs from clinical data for each protocol. 
The resulting insulin sensitivity profile, SI(t), varies hourly.  
2.3  Virtual Trials 
The “virtual trial” method is used to simulate a clinical 
trial using patient specific data such as insulin sensitivity, 
SI. The insulin sensitivity profile SI(t) captures a patient‟s 
time varying glycaemic response to insulin and nutrition 
inputs and is assumed to be an intrinsic property of the 
patient, independent of their glycaemic control 
interventions. This profile can then be used to simulate the 
blood glucose response to other combinations of insulin 
and dextrose inputs specified by a modified TGC protocol 
to obtain new glycaemic responses. Hence, an expected 
blood glucose profile can be generated for each patient to 
simulate glycaemic response to a specific protocol. Thus, 
virtual trials can be used to analyse, in-silico, the effect of 
different protocols on patient performance.  
In this analysis, 2 groups of virtual patients are created 
from clinical data: Groups A and B, defined by their 
treatment with the Glucontrol A (intensive) or Glucontrol 
B (conventional) protocol.  
This study performs two major forms of validation using 
virtual trials, as described schematically in Figs. 1-2: 
1. Self validation: This test assesses the ability of the 
in-silico virtual trials to reproduce the clinical data. 
Simulation results are compared to clinical results. 
Differences can be ascribed to model errors and/or 
lack of perfect compliance in the clinical study versus 
the perfect compliance and timing in-silico. 
2. Cross validation: This test assesses the assumption 
that the SI(t) insulin sensitivity profiles accurately 
capture patient dynamics, independent of the insulin 
and nutrition inputs used to create them. Hence, it 
tests the A protocol on B virtual patients, and the B 
protocol on A virtual patients. Since both cohorts are 
matched clinically, differences can be ascribed to 
failures in this critical, underlying independence 
assumption behind this virtual trials method.  
These two tests provide both per-patient and cohort-wide 
validation of this in-silico approach. 
1) Self-Validation: Self validation tests the ability to 
recreate the clinical data given the cohort of virtual 
patients and protocol definitions. For the self validation on 
Glucontrol A, the Glucontrol A protocol is simulated on 
Group A virtual patients, and these virtual trial results are 
compared to the clinical data of Group A. This step was 
repeated for self validation on Glucontrol B. Two virtual 
trials were simulated on each group considering a) the 
actual measurement timing used in retrospective trials 
(actual measurement) and b) actual measurement as 
suggested from the protocol (per protocol). Use of actual 
vs. per-protocol measurement timing allows one measure 
of compliance error.  
2) Cross-Validation: Cross validation uses the matched A 
and B cohorts to determine the ability of the modelling 
method to reproduce the clinical data on a matched, but 
independent, cohort. For example, protocol A is simulated 
on virtual patients derived from Group B clinical data. The 
results of this test are then compared to the clinical data of 
Glucontrol Group A. Similarly, protocol B is test on 
virtual patients of Group A and the results are compared to 
Group B clinical data. If patients were perfectly matched 
the in-silico results between groups would also match. 
Differences using large matched cohorts can thus be 
ascribed to how well the assumption holds that these 
virtual patient SI(t) profiles are independent of the clinical 
inputs used to derive them. If cross validation results 
match the clinical results well for clinically matched 
cohorts, then this assumption can be considered valid. 
 
3. RESULTS 
Fig. 3 shows the CDF of measured blood glucose on a 
cohort basis, comparing:  
1. The distribution of simulated BG from the virtual 
trials of the Glucontrol A protocol on virtual 
 
Group A 
Virtual patients 
Glucontrol A 
Control Protocol 
Simulation Code 
Group B 
Virtual patients 
Glucontrol B 
Control Protocol 
Simulation Code 
Self Validation: expect to generate original clinical data with 
differences being due to compliance or model errors 
 
Cross Validation: expect to generate clinical data of one group 
using virtual patients from another (matched) group with errors due 
to the validity of assuming independence of the virtual patients 
(SI(t)) from the clinical inputs used to identify it. 
Group A  
Clinical Data 
Self Validation 
Cross 
Validation 
Cross 
Validation 
Group B  
Clinical 
Data 
Group A  
Clinical Data 
Group B  
Clinical 
Data 
 
Fig. 2. Virtual trial validation method. Glucontrol A and 
Glucontrol B virtual trials are compared to the appropriate 
clinical results. 
 
  
     
 
patients of Group A (self validation) and Group B 
(cross validation). Both sets of results are compared 
to the clinical results of Group A. 
2. Simulated BG distribution from the virtual trials of 
Glucontrol B protocol on virtual patients of Group 
B (self validation) and Group A (cross validation), 
compared to Group B clinical results. 
Hence, Fig. 3 presents both the self and cross validation in-
silico results for both the A and B virtual cohorts.  
The breakdown of distributions shows a clear separation 
between the protocols for Glucontrol A and Glucontrol B 
for all combinations of simulations, as expected from the 
clinical results and trial design. The four distributions for 
the Glucontrol A protocol show particularly close 
agreement. The Glucontrol A clinical median cohort BG 
value of 6.2 mmol/L agrees well with the 6.0 mmol/L and 
6.2 mmol/L medians for the self validation trials using 
retrospective and per-protocol BG timing respectively.  
The cross-validation median BG of 6.5 mmol/L is also in 
close agreement with the clinical result. Similar agreement 
between clinical and simulation data are also present in the 
per-patient results in Table 2. 
The four BG distributions in Fig. 3 for the Glucontrol B 
protocol shows a slightly greater spread in results, 
particularly below the Group B target of 8 mmol/L. 
However, the median cohort clinical BG value of 8.1 still 
agrees well with the medians of 8.5 and 8.7 mmol/L for 
Glucontrol B self validation with actual measurement and 
per-protocol measurements respectively, and also agrees 
well with the cross-validation median result of 8.5 
mmol/L.  
Finally, the wider error below 8 mmol/L may be due to the 
fact that the Glucontrol B protocol requires zero 
exogenous insulin below its target. Hence, model error 
grows due to the population-constant fixed endogenous 
insulin rate assumed in this situation (IB in Equation (3)). 
Above 8 mmol/L, despite relatively low median insulin 
doses at 1 U/hr (Table 1), the agreement between BG 
distributions is much closer. Finally, as with the Group A 
results, the self- and cross-validation agreement is within 
measurement error and clinically insignificant at all 
likelihood (y-axis) levels of the CDF. 
Fig. 4 shows the same results for the CDF of the median 
patient blood glucose levels across all patients in each 
group. This “per-patient” comparison has the same whole-
cohort trend in Fig.3. Interestingly, and as with the cohort 
results, the largest gap is between the self validation and 
clinical data for Glucontrol B using retrospective 
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Fig. 3. CDF of blood glucose levels of clinical Glucontrol data versus virtual trials on a cohort basis. 
Table 2. Comparison of per-patient clinical results and 
virtual trial simulations (self-validation and cross 
validation) on Glucontrol A. Median [IQR] is used 
where appropriate. 
 Virtual Trials 
Simulation Clinical A 
GlucoA on A actual 
measurement 
GlucoA on A per 
protocol 
GlucoA on B per 
protocol 
No. of patients 142 142 142 69 
Per Patient  
Average insulin 
rate (U/hr) 1.4 [0.9 - 2.1]  1.9 [1.2 - 3.0] 2.6 [1.7 - 4.2] 4.6 [2.5 - 6.5]  
Average glucose 
rate (g/hr) 1.1 [0.5 - 7.6]  1.1 [0.5 - 7.6]  1.1 [0.5 - 7.6] 2.9 [0.7 - 7.4]  
BG (mmol/L) 6.4 [5.9 - 6.9] 6.1 [5.7 - 6.7] 6.3 [5.8 - 6.8] 6.6 [6.0 - 7.0] 
BG measures 4564 4564 9635 7414 
Measurement 
frequency 6.52 6.52 13.87 13.79  
 
Table 3. Comparison of per-patient clinical results and 
virtual trial simulations (self-validation and cross 
validation) on Glucontrol B. Median [IQR] is used 
where appropriate. 
 Virtual Trials 
Simulation Clinical B 
GlucoB on B actual 
measurement 
GlucoB on B per 
protocol 
GlucoB on A per 
protocol 
No. of patients 69 69 69 142 
Per Patient  
Average insulin 
rate (U/hr) 0.6 [0.3 - 1.2]  0.7 [0.4 - 1.3] 1.0 [0.4 - 1.9] 0.5 [0.1 - 1.2]  
Average glucose 
rate (g/hr) 2.9 [0.7 - 7.4]  2.9 [0.7 - 7.4]  3.0 [0.7 - 7.7] 1.1 [0.5 - 7.5]  
BG (mmol/L) 8.3 [7.6 - 8.8] 8.5 [8.1 - 8.8] 8.6 [8.3 - 9.2] 8.4 [8.0 - 8.9] 
BG measures 2820 2820 4083 5436 
Measurement 
frequency 5.23 5.23 7.62 7.86  
  
     
 
measurement timing. This result indicates the possibility of 
compliance error, whereas the difference between self-
validation using per-protocol timing to the clinical data 
provides a combination of model error and compliance 
error.  
Table 2 shows the comparison of clinical trials to the self 
validation and cross validation on Glucontrol A. Per 
patient results show a very close agreement between self 
validation per protocol to the clinical data given that the 
rate of insulin are almost doubled. For the cross validation, 
Glucontrol A protocol required higher rates of insulin for 
Group B, almost 3x compared to the clinical data. 
Comparison of clinical trials with self validation and cross 
validation on Glucontrol B is summarised in Table 3. Self 
validation results show close agreement to the clinical 
result and for cross validation, Group A insulin 
requirements are reflected by lower nutrition and higher 
target BG following the Glucontrol B protocol. Similarly, 
virtual trials of Glucontrol B per protocol have higher 
measurement frequency compared to the actual 
measurement. The differences in BG measurement 
frequency for clinical and self validation per protocol 
suggest that the protocol was not being followed clinically. 
4. DISCUSSION 
This paper focuses on the Glucontrol protocol from one 
centre (Liege, Belgium; pilot centre). Glucontrol was a 
multi-centre study stopped early to a high rate of 
unintended protocol violations (Preiser et al. 2009). This 
clinical data was independent from the Christchurch 
Hospital ICU data used in prior development and 
validation of the model used here.  More importantly, there 
are 2 cohorts matched by severity of illness, weight and 
sex, which had significantly different glycaemic targets 
and glycaemic control therapies.  
The virtual trials results are close to clinical results in all 
cases for both self validation and cross validation (Figs. 4 
and 5). Referring to the same figures, the obvious 
separation between two protocols indicates the inter-
protocol differences are, as expected, much larger than any 
inter-group differences. More importantly, the close 
correlation of self and cross validation results to clinical 
data validates the idea that these in-silico virtual trial 
simulations can accurately predict the expected clinical 
results of a protocol prior to clinical implementation using 
such virtual patients. 
The results in Figs. 3 and 4 illustrate some variation 
between clinical data and virtual trials. In particular, 
Glucontrol A simulation results are closer to clinical data 
compared to Glucontrol B data. The major difference is 
that protocol B uses much less insulin given its higher 
glycaemic target. Therefore, the impact of intrinsic and 
potentially variable patient-specific dynamics, such as 
endogenous insulin production (IB and kI), in Equation (3) 
are more pronounced with respect to the far lesser 
exogenous insulin given to Group B, especially at low 
blood glucose levels. As these metrics are, by necessity, 
assumed population constants, some of the Group B 
simulation errors may reflect errors in these population 
values.  
Another likely cause is evident in Fig. 4, where the most 
mismatched line of the three results is for Glucontrol B 
using measurements as per-protocol. While no specifics 
were reported for the compliance issues in Glucontrol, the 
larger gap seen in the Glucontrol B self and cross 
validation results is primarily at lower glycaemic levels 
below the target range of 8.0 mmol/L, where nursing 
compliance on an otherwise well controlled patient could 
have been less. The fact that the clinical data is lower than 
the simulations could indicate non-compliance in timing or 
dosing, or simple overriding of the protocol 
recommendations by clinical staff. Protocol compliance 
and model error together form discrepancies between self 
validation and clinical results. There are many factors that 
lead to the protocol compliance, such as timing errors and 
faulty or non-compliant insulin administration. In contrast, 
computer simulations will always follow protocols exactly 
as instructed. Hence, the self validation error captures both 
model and compliance errors. 
For the cross validation, protocol A on Group B is a very 
good match and close to the self validation results for 
Group A. In addition, protocol B on Group A virtual 
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Fig. 4. CDF of median blood glucose measured of Glucontrol clinical data versus virtual trial on a per patient basis. 
 
  
     
 
patients is within the tolerance defined in the Group B self 
validation and closer to the slope and trends of the clinical 
data. These results indicate that the cross validation is 
within self validation model and compliance errors. Thus, 
the insulin sensitivity independence assumption appears to 
hold for these virtual trials, independently validating this 
concept and the virtual trial method based on this model.  
Differences between self and cross validation results 
indicate remaining differences between patient groups 
despite clinical matching. More importantly, the relatively 
small differences show the strength of model-fitted insulin 
sensitivity as a description of patient metabolic state, 
rather than as a therapy-specific parameter value. The tight 
agreement in the cross validation results for cohorts 
matched in terms of clinical characteristics and metabolic 
dynamics (Fig. 3) adds weight to the use of these model-
based insulin sensitivity profiles, and thus this model, to 
accurately generate expected clinical outcomes in testing 
new protocols. 
Finally, this paper shows the potential for TGC to be 
readily optimised and implemented using model predictive 
control. Even though some TGC clinical trials have not 
achieved any benefit from TGC (Finfer et al. 2009), only 2 
protocols have been first optimized with virtual trials 
(Chase et al. 2007; LeCompte et al. 2009). Both delivered 
safe, effective TGC with reduced or zero hypoglycaemia. 
  
5.  CONCLUSIONS 
This paper presented the analysis and validation of an in-
silico virtual patient and model-based virtual trials 
methodology. It takes advantage of a set of independent 
clinical data comprised of two clinically matched cohorts 
treated with two different TGC protocols with two 
different glycaemic targets. It has 2 main conclusions that 
can be drawn: 
 The self validations indicated a clinically 
insignificant error in these virtual patient methods 
due to model and/or clinical compliance. 
 The cross validations clearly show the virtual 
patients enabled by the identified patient-specific 
SI(t) profiles are independent of the clinical inputs 
used to generate these profiles. 
 
Thus, the virtual patients and in-silico virtual trial methods 
presented are validated in their ability to accurately 
simulate, in advance, the clinical results of an independent 
TGC protocol, directly enabling rapid design and 
optimisation of safe and effective TGC protocols with 
confidence. 
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